We’re funding the UK participation of BIOMEDE, an international, adaptive clinical trial for children with Diffuse Midline Gliomas - pontine location (DMG, formerly known as DIPG).
The trial is the first of its kind because it requires the children to have a biopsy of the tumour, and based on the molecular traits of the tumour different treatments are assigned.
In the first instance of the trial, the molecular traits that are tested for are PTEN and EGFR, and the first drugs that will be tested are dasatanib, everolimus and erlotinib. The levels of PTEN and EGFR detected in the tumour biopsy will define which drug, or drugs, the child receives as part of their treatment.
The adaptive nature of this trial means that as new treatments become available for this kind of tumour, they can be added into the trial. This is key so that children get access to the new, potentially life-saving treatments faster.
There are three main reasons why this trial is so important.
This trial will help children with a diffuse midline glioma, now and in the future.
Research is the only way we will discover kinder, more effective treatments and, ultimately, stamp out brain tumours – for good! However, brain tumours are complex and research in to them takes a great deal of time and money.
Across the UK, over 100,000 families are facing the overwhelming diagnosis of a brain tumour and it is only through the generosity of people like you can we continue to help them.
But, by setting up a regular gift – as little as £2 per month - you can ensure that families no longer face this destructive disease.
We are very proud to be funding clinical trials like this one, but we aren't responsible for getting people onto them.
Different trials have different eligibility criteria, if you would like to explore this option please contact your medical team.
If you would like help with this conversation, or would like more general information please contact our support team.